(Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 |
Sales | 127,040 | 107,670 | 86,350 | 88,640 | 145,970 |
Sales Growth | +17.99% | +24.69% | -2.58% | -39.28% | +88.42% |
Net Income | -110,560 | -182,020 | -220,680 | -227,280 | -204,750 |
Net Income Growth | +39.26% | +17.52% | +2.90% | -11.00% | -14.49% |
Heron Therapeutics (HRTX)
1.7600 x 1 1.8900 x 1
Post-market by (Cboe BZX)
1.7700 +0.0400 (+2.31%) 02/24/25 [NASDAQ]
1.7600 x 1 1.8900 x 1
Post-market 1.7500 -0.0200 (-1.13%) 18:01 ET
for Mon, Feb 24th, 2025
Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA.
Fiscal Year End Date: 12/31